| General Information of Drug (ID:
DR0767) |
| Drug Name |
Gemtuzumab ozogamicin
|
| Synonyms |
Gemtuzumab; CMA-676; Gemtuzumab-Ozogamicin; Mylotarg; CMA676; CMA 676; Gemtuzumab Ozogamicin; D000079982 |
| Indication |
Acute myeloid leukaemia
[ICD11: 2A60]
|
Approved
|
[1]
|
| Cross-matching ID |
- PubChem CID
- 404336834
- TTD Drug ID
- D06EWO
|
|
|
|
|
|
|
|
| Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug |
| DME Name |
DME Info |
Species |
Uniprot ID |
EC Number |
REF |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
Homo sapiens
|
|
|
[2]
|
|
|
|
|
|
|
|
| References |
| 1 |
Gemtuzumab Ozogamicin was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
|
| 2 |
Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
